SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Xiaomi Shares Jump on Europe EV Expansion Plan 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
OpenAI Nears Astra AI Model Launch With Safety Focus 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Milei Threatens Falkland Oil Firms With Sanctions 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Add as a preferred source on Google
SAN ANTONIO, March 01, 2018 -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has been approved for membership in the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI). EDRN brings government, academic and industry leaders together to accelerate the discovery, development and validation of biomarkers for cancer risk and early detection.
“Collaboration with the National Cancer Institute’s Early Detection Research Network is an important step in the development of CyPath© Lung, our non-invasive, early-stage lung cancer test. EDRN also offers valuable resources to advance our promising oncological diagnostics for prostate and bladder cancers,” said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies. “EDRN and its members share many of our objectives, including expanding our knowledge of the biology of cancer, developing and testing promising technologies for the early detection of cancer, and promoting collaboration to advance the clinical application of tests like CyPath© Lung.”
bioAffinity Technologies’ Executive Vice President Vivienne Rebel, PhD, MD, and Director of Operations Xavier Reveles, MS GC(ASCP)cm, will attend next week’s 10th EDRN Scientific Workshop from March 6-8, 2018, in Bethesda, MD. The workshop will focus on standards and regulatory science, novel technologies for precision detection, imaging, clinical and validation science, alliances and consortia on biomarkers, and non-profit foundations’ support for biomarkers.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company that develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas San Antonio. The Company’s initial product is CyPath® Lung, a diagnostic assay for the detection of early-stage lung cancer.
Contact: Maria Zannes, 505.400.9747
